Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.59
- Piotroski Score 3.00
- Grade N/A
- Symbol (AVCO)
- Company Avalon GloboCare Corp.
- Price $0.53
- Changes Percentage (-16.52%)
- Change -$0.1
- Day Low $0.52
- Day High $0.65
- Year High $1.07
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.10
- Trailing P/E Ratio -5.1558823529412
- Forward P/E Ratio -5.1558823529412
- P/E Growth -5.1558823529412
- Net Income $-16,707,010
Income Statement
Quarterly
Annual
Latest News of AVCO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cavco Industries, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Cavco Industries (NASDAQ:CVCO) surpassed earnings expectations, with revenues reaching US$507m. Analysts predict a 5.4% revenue increase to US$1.95b in 2025, boosting EPS to US$19.32....
By Yahoo! Finance | 2 weeks ago -
Cavco Industries Inc (CVCO) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
CEO William Boor addressed production challenges due to disruptions in Florida and Georgia by prioritizing catching up on backlogs and monitoring retail activity recovery. Recent HUD code changes are ...
By Yahoo! Finance | 2 weeks ago -
Cavco Industries, Inc. (CVCO): A Good Home Builder Stock to Consider Buying Now
A list of the 10 Best Home Builder Stocks includes Cavco Industries, Inc. (NASDAQ:CVCO), comparing its standing to other stocks. Lower mortgage rates and the anticipated Fed rate cut are seen as posit...
By Yahoo! Finance | 2 months ago
